Palisade Bio (PALI) Gains from Investment Securities (2013 - 2023)
Palisade Bio's (PALI) quarterly Gains from Investment Securities came in at -$8000.0 in Q4 2023, down 102.39% on a QoQ basis from $334133.0 in Q1 2014.
Palisade Bio (PALI) Gains from Investment Securities (2013 - 2023) Analysis & Trends
Palisade Bio (PALI) has 3 years of Gains from Investment Securities data on file, last reported at -$8000.0 in Q4 2023.
- On a quarterly basis, Gains from Investment Securities changed N/A year-over-year to -$8000.0 in Q4 2023; TTM through Dec 2023 was -$8000.0, a N/A change from a year earlier, with the FY2023 full-year figure at $204000.0, changed N/A from the prior year.
- Gains from Investment Securities for Q4 2023 stood at -$8000.0, down from $334133.0 in the prior quarter.
- Over the last five years, Gains from Investment Securities for PALI reached as high as -$8000.0 in Q4 2023 and fell as low as -$8000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Palisade Bio | 424.57 Mn | 291.94 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -8,000.00 |
| Dec 31, 2023 | -8,000.00 |
| Mar 31, 2014 | 334,133.00 |
| Mar 31, 2014 | 334,133.00 |
| Dec 31, 2013 | 105,647.00 |
| Dec 31, 2013 | 105,647.00 |
| Sep 30, 2013 | 677,883.00 |
| Sep 30, 2013 | 677,883.00 |
| Jun 30, 2013 | 188,317.00 |
| Jun 30, 2013 | 188,317.00 |
| Mar 31, 2013 | -6,518.00 |
| Mar 31, 2013 | -6,518.00 |